Mittwoch, 24. August 2011

Was sind die grundsätzlichen Unterschiede in der Beratungskompetenz von Drogerie und Apotheke?

IQPC traf Jens Apermann exklusiv zum Interview. Jens Apermann ist Geschäftsführer der Iwan Budnikowsky Marketing GmbH. In dem Interview spricht er über Apothekenexklusivität und das Projekt Budni-Partner-Apotheken.


Die BUDNI-Partner-Apotheken arbeiten bereits seit 2003 im Netzwerk der Hamburger Partner-Apotheken zusammen. Durch die zusätzliche Kooperation mit BUDNIKOWSKY erhalten die Apotheken exklusiven Zugang zum erfolgreichsten Kundenbindungsprogramm Hamburgs, der BUDNI KARTE.

Das Interview wurde als Podcast aufgezeichnet. Klicken Sie hier um das Interview anzuhören.

Montag, 22. August 2011

Modified ecstasy 'attacks blood cancers'



Modified ecstasy could one day have a role to play in fighting some blood cancers, according to scientists.
Ecstasy is known to kill some cancer cells, but scientists have increased its effectiveness 100-fold, they said in Investigational New Drugs journal.

Their early study showed all leukaemia, lymphoma and myeloma cells could be killed in a test tube, but any treatment would be a decade away.

A charity said the findings were a "significant step forward".

In 2006, a research team at the University of Birmingham showed that ecstasy and anti-depressants such as Prozac had the potential to stop cancers growing.

The problem was that it needed doses so high they would have been fatal if given to people.

The researchers, in collaboration with the University of Western Australia, have chemically re-engineered ecstasy by taking some atoms away and putting new ones in their place.

One variant increased cancer-fighting effectiveness 100-fold. It means that if 100g of un-modified ecstasy was needed to get the desired effect, only 1g of the modified ecstasy would be needed to have the same effect.
Scientists say this also reduced the toxic effect on the brain.

Lead researcher Professor John Gordon, from the University of Birmingham, told the BBC: "Against the cancers, particularly the leukaemia, the lymphoma and the myeloma, where we've tested these new compounds we can wipe out 100% of the cancer cells in some cases.

"We would really need to pinpoint which are the most sensitive cases, but it has the potential to wipe out all the cancer cells in those examples.

"This is in the test tube, it could be different in the patient, but for now it's quite exciting."

'Soapy' cells
 
It is believed that the drug is attracted to the fat in the membranes of the cancerous cells.

Researchers think it makes the cells "a bit more soapy", which can break down the membrane and kill the cell.
They said cancerous cells were more susceptible than normal, healthy ones.

However, doctors are not going to start prescribing modified ecstasy to cancer patients in the near future.
The research has been demonstrated only in samples in a test tube. Animals studies and clinical trials would be needed before prescribing a drug could be considered.

First, however, chemists in the UK and Australia are going to try to tweak the modified ecstasy even further as they think it can be made even more potent.

'Genuinely exciting'
 
If everything is successful, a drug is still at least a decade away.

Dr David Grant, scientific director of the charity Leukaemia and Lymphoma Research, said: "The prospect of being able to target blood cancer with a drug derived from ecstasy is a genuinely exciting proposition.

"Many types of lymphoma remain hard to treat and non-toxic drugs which are both effective and have few side effects are desperately needed.

"Further work is required but this research is a significant step forward in developing a potential new cancer drug."

Freitag, 19. August 2011

Pharma Sales Force "Sommerspecial"

"Zwei kommen - Einer zahlt!"

Melden Sie sich und Ihren Kollegen jetzt mit dem "2 for 1"-Ticket zum Jahreskongress an. Egal, welches Paket Sie zu zweit buchen - Sie sparen einen gesamten Eintrittpreis!

Aber Achtung! Das Sommerspecial-Angebot gilt nur bis zum 31. August 2011!

TOPTHEMEN PHARMA SALES FORCE 2011

Diskutieren Sie mit Experten der Branche Konzepte und Entwicklungen im Pharmavertrieb. Die diesjährigen Kongress-Schwerpunkte sind:

- Auf der Suche nach dem New Commercial Model - ist Collaborative Healthcare die Lösung?

- Effizienz- und Wertschöpfungspotenziale im Vertrieb realisieren: Welche Konzepte sind zielführend?

- Market Access und frühe Nutzenbewertung - wie soll sich die Industrie auf die Konsequenzen von AMNOG vorbereiten?

- CRM, Closed Loop Marketing, Social Media: Wo passt welche Multi Channel Strategie?

- Key Account Management: Hat die Umstellung auf KAM-Strukturen die gewünschten Erfolge gebracht?

Weitere Informationen finden Sie hier.


Donnerstag, 18. August 2011

Dogs Sniff Out Lung Cancer in Humans

Study Shows Some Dogs Can Be Trained to Identify Lung   Cancer When They Sniff a Person's Breath

Close up of dogs nose By Brenda Goodman, WebMD Health News,Reviewed by Laura J. Martin, MD
Aug. 17, 2011

German researchers say that highly trained dogs are able to reliably sniff out lung cancer in human breath.

In its early stages, lung cancer has few symptoms, making it difficult for doctors to catch it early, when it's still treatable.

"This is the holy grail," says Suresh S. Ramalingam, MD, associate professor and director of the lung program at Emory University's Winship Cancer Institute in Atlanta.

"The whole field is focused on using something that's readily available that does not involve an expensive surgery or scan that would allow us to find early cancers," says Ramalingam, who is developing technology that aims to replicate the ability of dogs to smell trace amount of chemicals produced by cancerous tumors. He was not involved in the research.

Recently a large, government-funded study found that longtime smokers at high risk for lung cancer who received annual rapid computed tomography (CT) scans of their lungs cut their risk of dying of the disease by 20%.

But that test has caused controversy because it falsely detects cancer in about one out of four people, leading to further invasive procedures.

Checking for Lung Cancer

The new study, which is published in the European Respiratory Journal, found that four trained dogs -- two German shepherds, an Australian shepherd, and a Labrador retriever -- correctly identified cancer in 71 of 100 samples from lung cancer patients.

They also ruled out cancer in 372 out of 400 samples that were known not to have cancer, giving them a very low rate of false positives, about 7%.

"The surprising result of our study is the very high specificity of our dogs to identify lung cancer," says study researcher Thorsten Walles, MD, a lung surgeon at Schillerhoehe Hospital in Gerlingen, Germany.
"It even surpasses the combination of chest computed tomography (CT) scan and bronchoscopy, which is an invasive procedure that needs some form of anesthesia," Walles tells WebMD in an email.

Doctors have previously reported cases in which dogs have alerted their owners to undiagnosed skin, breast, and lung cancers by repeatedly pawing or nosing an affected body part. Some dogs have even been trained to smell low blood sugar levels in people who have diabetes.

But dogs have had more mixed success in carefully controlled studies, where samples from healthy people and sick people have been mixed.

A study published in BMJ in 2004 found that dogs correctly identified bladder cancer an average of about 40% of the time, a rate that was better than the 14% accuracy that could be expected by chance, but was lower than available tests.

But in June, researchers in Japan reported that dogs could detect the presence of colon cancer in human breath and stool samples with nearly 90% accuracy, a success rate only slightly lower than colonoscopy.

Checking for Lung Cancer continued...

The length of time the dogs are trained may be an important difference between the studies, Walles says. In his study, the four dogs were trained for nine months. Other studies have used dogs trained for as little as three weeks.

The kind of sample the dogs are asked to smell -- urine, breath, blood, or stool -- may also influence the results, he says.

In his study, 220 volunteers -- 110 who were healthy, 60 who had lung cancer, and 50 with chronic obstructive pulmonary disease (COPD) -- were asked to exhale into a glass tube filled with fleece.

The tubes were mixed up so neither the dogs' handlers nor two observers who placed the samples on the floor in front of the dogs knew the status of the person they were from, to avoid inadvertently giving the dogs clues about what they should find.

The dogs were presented with five tubes at a time. Only one contained a sample from a person with cancer.
The dogs were trained to lie down and put their nose to the tube if they detected lung cancer.

The dogs appeared to be able to accurately identify the samples from cancer patients, even when they were in very early stages of the disease. And they were able to pick up the scent despite competing odors of cigarette smoke or food on a person's breath.

How Dogs Detect Cancer

Researchers think dogs and other animals are able to smell disease by picking up on minute changes in compounds called volatile organic compounds (VOCs) that comprise chemical signatures in the body.
As many as 4,000 different VOCs, for example, have been identified in human breath.

A dog's sense of smell has been estimated to be 100 to 1,000 times more powerful than a human's, says Gary K. Beauchamp, PhD, director of the Monell Chemical Senses Center in Philadelphia.

"It's not just how sensitive their nose is. It's how they process this into a recognition pattern," Beauchamp says. "The reason dogs can do this is that they're recognizing a complex picture, and that's the big trick, to find out how to mimic that in some sort of device that could be useful for diagnostic purposes in human disease."
Other researchers agree.

Ramalingam says because success rates vary between dogs and between samples, the real value of knowing dogs can detect cancer will likely be in building technology that can reliably repeat what they can do.
"The dogs show that it can be done. We need to find out what the dogs are sniffing so we can do it in a more scientific manner."

Mittwoch, 17. August 2011

How to deal with medicine counterfeiting?

Counterfeiting especially in regards to medicine is not only posing a big problem to the pharma industry, but is also life-threatening for the end-users. What is the best system to combat counterfeits? Is using end-to-end systems or is track'n'trace the answer?

In our download center you can find many free articles, presentations, interviews and whitepapers on this subject, for example:

Handling des Datenvolumens im 2-SM
Securing the Supply Chain to Combat Counterfeit Medicines
Counterfeit medicines present a serious challenge for the pharmaceutical industry. As well as the dangers to public health presented by such drugs, the presence of counterfeit medicines serves to reduce confidence within the pharmaceutical industry as a whole.
Handling des Datenvolumens im 2-SM
Ensuring a Secure and Compliant Pharmaceutical Supply Chain
As pharmaceutical companies keep moving on the path of globalizing their operations and product development, they must be prepared to manage the challenges that are inherent in such a supply chain. The primary challenges include an increase in illicit activities (e.g. counterfeiting, piracy, adultery), increased safety concerns for the consumer, a tough regulatory environment, and an ever increasing degree of complexity on account of globalization.
Handling des Datenvolumens im 2-SM
Current legislative and regulatory infrastructure - in the context of pharmaceutical product tracking
Depending upon the various types of drug packs and formats, there are various problems associated with the tracking and tracing of pharmaceutical products especially when tracking a single item. In Europe, blister packs are used, while in the USA containers of tablets are used and the information is coded on the container, not on a per item kind of basis.


Visit the website for more information on this subject: Pharma Track & Trace.

Mittwoch, 10. August 2011

Engineer your way to increased productivity of your sales force

Learn how you can apply Six Sigma to your sales force to increase productivity! In this Profit through Process podcast, Genna Weiss of Six Sigma IQ, speaks with Justin Hitt, Strategic Relations Consultant for JWH Consolidated Inc., who discusses how Six Sigma and other engineering processes can help complement traditional methods of increasing selling productivity and establish accountable, consistent and measurable results for your sales person’s performance.

The complete interview has been recorded as a podcast. You can listen to it here. It is also available as a download here.

Dienstag, 9. August 2011

Pharmabranche zahlt zwei Milliarden Euro

von Maike Telgheder (Handelsblatt)

Vor einem Jahr wurden die Zwangsrabatte auf verschreibungspflichtige Arzneimittel von 6 auf 16 Prozent erhöht. Das hatte Folgen: Die deutsche Pharmaindustrie musste zwei Milliarden Euro Rabatt gewähren.

Die Pharmaindustrie in Deutschland muss in diesem Jahr mehr als zwei Milliarden Euro Rabatt auf ihre verschreibungspflichtigen Medikamente gewähren. Das sind 1,2 Milliarden mehr als noch im vergangenen Jahr, bei einem Branchenumsatz von 18 Milliarden Euro. Das zeigen aktuelle Berechnungen des Marktforschungsinstituts IMS Health, die dem Handelsblatt exklusiv vorliegen. Hintergrund ist die vor einem Jahr in Kraft getretene Regelung, nach der die Zwangsrabatte für verschreibungspflichtige Arzneimittel von 6 auf 16 Prozent erhöht wurden.

In der exklusiv für das Handelsblatt erhobenen Auswertung hat IMS ermittelt, dass im ersten Halbjahr dieses Jahres rund 27 Prozent des Rabattvolumen in Höhe von 1,14 Milliarden Euro auf allein fünf Unternehmen entfällt: Pfizer, Novartis, Roche, MSD und Astra Zeneca mussten den gesetzliche Krankenkassen danach durchschnittlich 60 Millionen Euro Rabatt gewähren.

Aufs Jahr hochgerechnet, müssen die fünf großen Firmen also jeweils mit durchschnittlich 120 Millionen Euro weniger Einnahmen rechnen, bei Deutschlandumsätzen von eine bis drei Milliarden Euro. Die Zwangsrabatte treffen allerdings eine Branche, die gut verdient. Die durchschnittliche Gewinnmarge vor Zinsen und Steuern (EBIT) der 20 weltgrößten Pharmafirmen liegt bei 24 Prozent. Zum Vergleich: Die Automobilindustrie kommt auf 4,6 Prozent.

Montag, 8. August 2011

Exclusive Podcast Series: Preclinical to clinical translation - the "tool" box

In our exclusive three-part podcast series, Prof. Martin Wehling, Managing Director at the University of Heidelberg’s Institute for Experimental & Clinical Pharmacology, speaks about current developments and challenges in translational medicine today.

Follow the links to download the podcast or to listen online:

Interview Martin WehlingInterview Martin WehlingInterview Martin WehlingPreclinical to clinical translation - the “tool box” (Part 1) In part one of our three-part podcast series, Prof. Martin Wehling, Managing Director at the University of Heidelberg’s Institute for Experimental & Clinical Pharmacology, speaks about current developments and challenges in translational medicine today.


Preclinical to clinical translation - the “tool box” (Part 2) In part two of our three-part podcast series, Prof. Wehling speaks about the standardized translational “tool box”, the current efficacy of physiologically based pharmacokinetic modelling (PBPK), and the relevance of biomarkers to translational processes.


Preclinical to clinical translation - the “tool box” (Part 3) In the third and final part of our podcast series on the preclinical to clinical translation tool box, Prof. Wehling gives insight into the role of pharmaceutical industry, joint public-private ventures and the future of Preclinical to clinical translation.

Mittwoch, 3. August 2011

Angewandte Regelung und Optimierung in der Prozessindustrie

Why bother? Bringen Optimierungsprojekte überhaupt was? Und wie berechnet man den Nutzen einer Lösung? In der folgenden 53-Seitigen Präsentation gibt Alexander Horch Antworten, z.B.:

Nutzen gehobener Lösungen - Das Potenzial ist gigantisch.
  • Viele Optimierungen sind noch nicht realisiert.
  • Schätzungen sagen Einsparungen von ca. 5 Billionen USD nur in Nordamerika voraus, wenn alle Regelungen optimal funktionierten.
  • Die Prozessindustrie verändert sich ständig, daher gibt es ständiges Verbesserungspotenzial.
  • Energieeffizienz in der Prozessindustrie war bislang kaum ein Thema. Der Fokus lag auf Maximierung der Produktion.
  • Optimierungen für Teillastbetrieb sind kaum existent.
  • Optimierungsverfahren für neue Produktionsverfahren (z.B. Kunststoffe aus Biomasse) sind noch nicht existent.
  • Vorhandene Anlagen, oft älter als 30 Jahre laufen bei Weitem nicht optimal.

Nutzen gehobener Lösungen - Wann nützt eine Lösung?
  • Einsparung von Einsatz- und Hilfsstoffen
  • Einsparung von Energie, Wasser, …
  • Einsparung von Emissionen (NOx, CO2, CO, SO2, …)
  • Personalentlastung (oft keine direkte Einsparung)
  • Verbesserte Produktqualität
  • Anlagenschonung, verlängerte Laufzeit, größere
  • Wartungsintervalle
  • Verbesserte Produktionsrate
  • Erhöhung der Anlagenverfügbarkeit, Vermeidung von Stillständen
  • Verbesserte Anlagensicherheit
  • Flexibilisierung der Produktion

Laden Sie sich jetzt diese interessante Präsentation für weitere Details herunter:  Angewandte Regelung und Optimierung in der Prozessindustrie


Tip: Interessiert an: Plant Asset Management? Klicken Sie hier für kostenlose Whitepaper, Präsentationen und Artikel.

Dienstag, 2. August 2011

Welche Konsequenzen hat das AMNOG auf die Vetriebsstrategien der deutschen Pharmaindustrie?

Von Seiten der Pharmaindustrie wurde die Entstehung des Arzneimittelneuordnungsgesetzes (AMNOG) kritisch begleitet. Vor allem die Regelungen zur frühen Nutzenbewertung stehen nach wie vor in der Kritik. In einem exklusiven Interview mit IQPC spricht Dr. med. Steffen Wahler, Vice President Clinical Outcomes & Reimbursement bei der Iroko Cardio GmbH, über die Konsequenzen, die die Neuordnung für die Entwicklung innovativer Arzneimittel hat.

Sein bisheriges Fazit zur Umsetzung des neuen Gesetzes fällt eher kritisch aus: „Es ist noch nichts passiert, da noch kein einziges Produkt durch das Raster des AMNOG endgültig gelaufen ist und man von daher keine endgültigen Aussagen machen kann“. Außerdem seien die an die Industrie gestellten Anforderungen, um ein Produkt auf den deutschen Markt zu bringen, sehr komplex. Darüber hinaus gibt es starke formale und inhaltliche Abweichungen zum europäischen und weltweiten Verständnis von „Dossiers“. Für den nationalen Markt seien die vielen üblichen Sonderaufwendungen im Zuge dessen für eine sinnvolle Preisfindung wenig hilfreich.

Des Weiteren spricht Dr. Wahler über potenzielle Probleme in der Preisverhandlung zwischen Industrie und GKV-Spitzenverband. So gibt er schließlich Hinweise für eine gelungene Unternehmensaufstellung, damit die Chancen des AMNOG zum Tragen kommen.

Um das gesamte Interview zu hören, klicken Sie hier. Weitere Informationen, Artikel und das ausführliche Konferenzprogramm zum 7. Jahresforum Pharma Sales Force 2011 finden Sie auf der Website.